Industry archive
Industry
React4life enters US medical-countermeasure programme with organ-on-chip models
A US prototype agreement will test microphysiological systems for chemical, biological, radiological and nuclear medical-countermeasure development.
HCMX EditorialMolecular Devices and STEMCELL automate an intestinal organoid workflow
A validated IntestiCult Plus workflow on the CellXpress.ai platform targets one of organoid adoption's most persistent barriers: routine, reproducible handling at scale.
HCMX EditorialHeartBeat.bio and Cubase Bio bring 3D spatial transcriptomics to Cardioids
The FACTS-3D collaboration will combine cardiac organoids with true-3D spatial transcriptomics to study fibrosis and heart-failure drug responses.
HCMX EditorialMatTek joins the Industry Alliance for Microphysiological Systems
MatTek's membership gives the alliance a tenth company and adds established human 3D tissue models to its work on regulatory acceptance and deployment of MPS.
HCMX EditorialEMA opens a voluntary route for early feedback on NAM data
A new pilot lets companies, method developers, CROs and academic groups submit NAM evidence outside a marketing application for non-binding regulatory feedback.
HCMX EditorialCartherics and Zucker Institute pair an iPSC cell platform with tissue-factor targeting
A new research and option agreement will test whether Cartherics' engineered, iPSC-derived natural killer cells can be combined with an anti-tissue-factor antibody for solid tumours and endometriosis.
HCMX Editorialbit.bio opens industrial-scale CRISPR screening in human iPSC-derived cells
bit.bio has launched ioScreen, a service intended to give drug-discovery teams access to large CRISPR screens in mature human iPSC-derived cells without building the capability in-house.
HCMX EditorialHeartBeat.bio and Molecular Devices package cardiac organoids for scalable safety studies
The companies have announced two 3D Ready Cardioid Supplement Kits designed to generate beating iPSC-derived cardiac organoids in manual or automated workflows.
HCMX EditorialBruker takes majority stake in organ-on-chip specialist MIMETAS
Bruker's majority investment in MIMETAS brings high-throughput human tissue and organ-on-chip models alongside multiomics, spatial biology, NMR and imaging technologies.
HCMX EditorialHopstem secures first Series C close for iPSC-derived neural cell therapy
Hopstem says the first close of its Series C will support clinical development and commercial manufacturing of its iPSC-derived forebrain neural progenitor programme.
HCMX Editorial